These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 30451018)

  • 1. Prostaglandin E1 overdose in a term neonate with congenital heart disease.
    Gorodetsky RM; Toole BM; Schult RF; Wiegand TJ
    Clin Toxicol (Phila); 2019 Jun; 57(6):420-421. PubMed ID: 30451018
    [No Abstract]   [Full Text] [Related]  

  • 2. Alarming medication error with prostaglandin E1 (PGE1) in a term neonate with critical congenital heart disease.
    Patra S; Patwal P; Chetan C; Gupta G
    BMJ Case Rep; 2024 Apr; 17(4):. PubMed ID: 38589246
    [No Abstract]   [Full Text] [Related]  

  • 3. Cortical Hyperostosis after Long-Lasting Prostaglandin E1 Treatment in a Newborn with Complex Congenital Heart Disease.
    Celona A; Giardina C; Pappalardo S; Secinaro A; Oreto L; Agati S; Romeo P
    J Pediatr; 2020 Nov; 226():302-303. PubMed ID: 32721399
    [No Abstract]   [Full Text] [Related]  

  • 4. Cortical hyperostosis simulating osteomyelitis after short-term prostaglandin E1 infusion.
    Kalloghlian AK; Frayha HH; deMoor MM
    Eur J Pediatr; 1996 Mar; 155(3):173-4. PubMed ID: 8929722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered prostaglandin E1 dosage during extracorporeal membrane oxygenation in a newborn with ductal-dependent congenital heart disease.
    Stone DM; Frattarelli DA; Karthikeyan S; Johnson YR; Chintala K
    Pediatr Cardiol; 2006; 27(3):360-3. PubMed ID: 16565906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Prostaglandin E1 Infusion for Newborns with Critical Congenital Heart Disease.
    Aykanat A; Yavuz T; Özalkaya E; Topçuoğlu S; Ovalı F; Karatekin G
    Pediatr Cardiol; 2016 Jan; 37(1):131-4. PubMed ID: 26260095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of low dose prostaglandin E1 treatment for ductus dependent congenital heart disease.
    Kramer HH; Sommer M; Rammos S; Krogmann O
    Eur J Pediatr; 1995 Sep; 154(9):700-7. PubMed ID: 8582419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostaglandin E1: first stage palliation in neonates with congenital cardiac defects.
    Reddy SC; Saxena A
    Indian J Pediatr; 1998; 65(2):211-6. PubMed ID: 10771966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostaglandin E1 in suspected ductus dependent cardiac malformation.
    Hallidie-Smith KA
    Arch Dis Child; 1984 Nov; 59(11):1020-6. PubMed ID: 6542338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complications of Long-Term Prostaglandin E1 Use in Newborns With Ductal-Dependent Critical Congenital Heart Disease.
    Alhussin W; Verklan MT
    J Perinat Neonatal Nurs; 2016; 30(1):73-9. PubMed ID: 26813395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term prostaglandin E1 use in newborns with duct-dependent congenital heart diseases: one year experience of a tertiary neonatal intensive care unit in Turkey.
    Ustün N; Dilli D; Zenciroğlu A; Okumuş N; Cınar G; Ozgür S; Koç M
    Anadolu Kardiyol Derg; 2013 Nov; 13(7):732-4. PubMed ID: 24172809
    [No Abstract]   [Full Text] [Related]  

  • 12. Prostaglandin E1 in infants with critical congenital heart disease.
    Dungan WT
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1985 Jan; 1(1):71-4. PubMed ID: 2454319
    [No Abstract]   [Full Text] [Related]  

  • 13. Brown fat necrosis in the setting of congenital heart disease and prostaglandin E1 use: a case report.
    Raboi CA; Smith W
    Pediatr Radiol; 1999 Jan; 29(1):61-3. PubMed ID: 9880620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostaglandin E1 in infants with congenital heart disease: Indian experience.
    Saxena A; Sharma M; Kothari SS; Juneja R; Reddy SC; Sharma R; Bhan A; Venugopal P
    Indian Pediatr; 1998 Nov; 35(11):1063-9. PubMed ID: 10216540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostaglandin E1 treatment in patent ductus arteriosus dependent congenital heart defects.
    Tálosi G; Katona M; Rácz K; Kertész E; Onozó B; Túri S
    J Perinat Med; 2004; 32(4):368-74. PubMed ID: 15346826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enteral feeding in prostaglandin-dependent neonates: is it a safe practice?
    Willis L; Thureen P; Kaufman J; Wymore E; Skillman H; da Cruz E
    J Pediatr; 2008 Dec; 153(6):867-9. PubMed ID: 19014824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neonatal transport issues with prostaglandin E1 infusions.
    Grubbs TC; Kraft NL
    Air Med J; 2002; 21(3):8-12. PubMed ID: 11994726
    [No Abstract]   [Full Text] [Related]  

  • 18. Reversibility of cortical hyperostosis following long-term prostaglandin E1 therapy in infants with ductus-dependent congenital heart disease.
    Høst A; Halken S; Andersen PE
    Pediatr Radiol; 1988; 18(2):149-53. PubMed ID: 3281113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostaglandin E1 use during neonatal transfer: potential beneficial role in persistent pulmonary hypertension of the newborn.
    Gupta N; Kamlin CO; Cheung M; Stewart M; Patel N
    Arch Dis Child Fetal Neonatal Ed; 2013 Mar; 98(2):F186-8. PubMed ID: 23235993
    [No Abstract]   [Full Text] [Related]  

  • 20. Pseudo-Bartter syndrome in a neonate on prostaglandin infusion.
    Eur J Pediatr; ; . PubMed ID: 12811550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.